February 3, 2020 10:10 AM EST

GAO report raises questions about reauthorizing two PRV programs

Zachary Brennan

Senior Editor

With the rare pediatric disease and medical countermeasure priority review voucher (PRV) programs set to expire by 2022 and 2023, respectively, the Government Accountability Office …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GAO report raises questions about reauthorizing two PRV programs

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Chicago’s biotech scene is growing up. What’s fueling it?

Major PBM reforms feature in Congress' year-end spending bill

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Jazz Pharmaceuticals CEO and co-founder Bruce Cozadd is retiring

UCB, Novartis say a Phase 2a Parkinson's study failed

GAO re­port rais­es ques­tions about reau­tho­riz­ing two PRV pro­grams

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

GAO report raises questions about reauthorizing two PRV programs

Chicago’s biotech scene is growing up. What’s fueling it?

Major PBM reforms feature in Congress' year-end spending bill

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Jazz Pharmaceuticals CEO and co-founder Bruce Cozadd is retiring

UCB, Novartis say a Phase 2a Parkinson's study failed